Rolf Larsson
Impact in
- Oncology top 0.5%
- Peptidase Inhibition and Analysis
- Hematology top 1%
Papers in
-
- Cancer therapeutics and mechanisms 27
- Metabolism, Diabetes, and Cancer 15
- Oncology 91
- Peptidase Inhibition and Analysis 18
- Drug Transport and Resistance Mechanisms 17
- Co-authors
- Peter Nygren (141 shared papers)Joachim Gullbo (46 shared papers)Mårten Fryknäs (60 shared papers)Bo Nilsson (17 shared papers)Malin Wickström (19 shared papers)Graciela Elgue (13 shared papers)Olle Korsgren (6 shared papers)Stig Linder (21 shared papers)
- Journals
- Anti-Cancer Drugs (18 papers)Biochemical Pharmacology (12 papers)International Journal of Cancer (12 papers)Oncotarget (7 papers)Cancer Chemotherapy and Pharmacology (6 papers)
- Partner nations
- SwedenUnited StatesNorway
In The Last Decade
Rolf Larsson
303 papers receiving 10.0k citations
Peers
Comparison fields: 5 of 151
- Oncology 2.3k
- Hematology 827
- Molecular Biology 4.7k
- Cancer Research 915
- Geriatrics and Gerontology 163
Countries citing papers authored by Rolf Larsson
This map shows the geographic impact of Rolf Larsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Larsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Larsson more than expected).
Fields of papers citing papers by Rolf Larsson
This network shows the impact of papers produced by Rolf Larsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Larsson. The network helps show where Rolf Larsson may publish in the future.
Co-authors
The 25 scholars most cited alongside Rolf Larsson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 306 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 414 | |
| 2 | 2010 | 297 | |
| 3 | 2000 | 282 | |
| 4 | Cyclotides: a novel type of cytotoxic agents. | 2002 | 232 |
| 5 | 2002 | 221 | |
| 6 | 1992 | 214 | |
| 7 | 2014 | 198 | |
| 8 | 2008 | 195 | |
| 9 | 2000 | 173 | |
| 10 | 2003 | 158 | |
| 11 | 1999 | 153 | |
| 12 | 2012 | 149 | |
| 13 | 2009 | 142 | |
| 14 | 2015 | 119 | |
| 15 | Alpha terpineol: a potential anticancer agent which acts through suppressing NF-kappaB signalling. | 2010 | 117 |
| 16 | 2002 | 116 | |
| 17 | 1998 | 112 | |
| 18 | 1999 | 110 | |
| 19 | Translocation and enhancement of phosphotransferase activity of protein kinase C following exposure in mouse epidermal cells to oxidants. | 1989 | 108 |
| 20 | 2013 | 106 |
About Rolf Larsson
Rolf Larsson is a scholar working on Molecular Biology, Oncology, Cancer Research, Hematology and Surgery, having authored 306 papers that have together received 10.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (27 papers), Cancer, Hypoxia, and Metabolism (19 papers), Acute Lymphoblastic Leukemia research (18 papers), Peptidase Inhibition and Analysis (18 papers), Drug Transport and Resistance Mechanisms (17 papers), Parathyroid Disorders and Treatments (17 papers), Acute Myeloid Leukemia Research (16 papers) and Metabolism, Diabetes, and Cancer (15 papers). The work is most often cited by research in Oncology (2.3k citations), Hematology (827 citations), Molecular Biology (4.7k citations), Cancer Research (915 citations) and Geriatrics and Gerontology (163 citations). Rolf Larsson has collaborated with scholars based in Sweden, United States and Norway. Frequent co-authors include Peter Nygren, Joachim Gullbo, Mårten Fryknäs, Bo Nilsson, Malin Wickström, Graciela Elgue, Olle Korsgren, Stig Linder, Linda Rickardson and Kristina Nilsson Ekdahl. Their work appears in journals such as Anti-Cancer Drugs, Biochemical Pharmacology, International Journal of Cancer, Oncotarget and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.